This article aims to address both the identified benefits
and the potential limitations to treatment fidelity reporting
by examining treatment fidelity in the context of the Family
Colorectal Cancer Awareness and Risk Education (Family
CARE) Project, a randomized controlled trial of an innovative
telehealth intervention that aimed to improve colonoscopy
uptake in individuals considered to be at intermediate
risk of familial colorectal cancer (CRC). Specifically, we
examined and evaluated treatment fidelity as defined according
to the five best-practice areas (Bellg et al., 2004, Borrelli
et al., 2005). We also identified and assessed potential limitations
to existing treatment fidelity measures, and discuss the
translatability of our intervention to future research and clinical
practice.